Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05833217 · ClinicalTrials.gov registry record · NA
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
A NA study of Insulin Resistance and Long COVID, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT05833217: Recruiting NA study of Insulin Resistance and Long COVID, sponsored by Stanford University.
NCT05833217 is a NA study of Insulin Resistance and Long COVID that is actively recruiting participants, run by Stanford University. The registered enrollment target is 55 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05833217, a NA study of Insulin Resistance and Long COVID, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Primary Outcome
Investigate the relationship between insulin resistance, as described by triglyceride/HDL-cholesterol ratio, and incident PASC (long COVID).
Conditions Studied
Interventions
- PROCEDURE Adipose Tissue Biopsy
- DIAGNOSTIC_TEST Steady State Plasma Glucose (SSPG) Test
Study Locations (2)
California
- Clinical and Translational Research Unit - Palo Alto
- Stanford Health - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT05833217 shows while recruiting
NCT05833217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 2 interventions - of which Adipose Tissue Biopsy is the first listed.
NCT05833217 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05833217 about?
NCT05833217 is a clinical study titled "Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2". The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir ...
What is the current status of trial NCT05833217?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2023-06-06. Estimated completion is 2025-12-31.
What conditions does trial NCT05833217 study?
This clinical trial studies the following conditions: Insulin Resistance, Long COVID, Insulin Sensitivity.
What interventions are being tested in trial NCT05833217?
The interventions under investigation include: Adipose Tissue Biopsy (PROCEDURE), Steady State Plasma Glucose (SSPG) Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05833217?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05833217 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05833217's enrollment target sits among peer trials
55 58th of 120 higher than 62 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI